Navigation Links
ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Date:12/10/2009

LEUVEN, Belgium, December 11 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, announces today that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) Age-related Macular Degeneration (AMD).

Wet AMD affects approximately five million patients worldwide and this patient population is continuing to grow. Wet AMD occurs when abnormal blood vessels behind the retina start to grow under the macula, the central area of the retina responsible for detailed vision. These blood vessels are often fragile and can leak blood and fluid below the macula, causing damage to the photoreceptors and vision loss. AMD, a disease associated with aging, gradually destroys a patient's vision. It is the most common cause of vision loss in patients aged 50 or older, and represents a market of over $1 billion annually.

Abnormalities in the vitreomacular interface (the interface of the vitreous and macula) have been implicated in wet AMD, and recent publications have demonstrated that approximately one-third of AMD patients have focal vitreomacular adhesion (VMA). VMA is a condition in which the vitreous gel, in the center of the eye, has an abnormally strong adhesion to the retina at the back of the eye, and research has found that this adhesion occurs in the same location as the wet AMD pathology.[1]

ThromboGenics is developing microplasmin as a non-surgical treatment for vitreomacular adhesion. Microplasmin has the potential to separate the vitreous from the retina and, as wet AMD is thought to result from the abnormal connection of the vitreous to the retina, it is therefore anticipated that microplasmin could potentially prevent the progression of this highly prevalent disease.

The MIVI 5 (Microplasmin for IntraVitreous Injection) trial is a P
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
2. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
3. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
4. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
7. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
8. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
11. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 Kepner-Tregoe (KT), ... announced that 13-year veteran Chris Geraghty ... Geraghty,s experience includes more than 20 years serving ... with manufacturing organizations. He succeeds Ray ... as Kepner-Tregoe,s Chairman of the Board and CEO. ...
(Date:5/21/2013)... , May 21, 2013  IsoRay, Inc. (AMEX: ... that it has entered into an exclusive international distribution ... complete product line in Greece . ... seed brachytherapy and medical radioisotope applications for brain cancer, ... gynecologic ("gyn") cancer. IASIS Medical is ...
(Date:5/21/2013)... Inc. (OTC BB: VASO) (the "Company"), a diversified medical technology ... devices and in the domestic sale of diagnostic imaging products, ... President and CEO of Vasomedical, Inc. will present at the ... 2013 in New York City at ... is scheduled to begin at 9:30 a.m. EDT. ...
Breaking Medicine Technology:Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2
... Nephros, Inc. (OTC Bulletin Board: NEPH ... products for therapeutic applications, infection control, and water purification, ... reverse split of its common stock will take effect ... 2011. Nephros common stock will be quoted on the ...
... The Florida Society of Pain Management Providers ( www.Flspmp.org ... use in the United States. Until now these statistics ...  Oxycodone dispensed in U.S. 2009 by state (per 100,000 ... FDA.Translation from grams to 15mg tablets for comparison purposes ...
Cached Medicine Technology:Nephros Announces Completion of Reverse Stock Split 2Nephros Announces Completion of Reverse Stock Split 3Nephros Announces Completion of Reverse Stock Split 4Florida Pain Clinic Society: 3.7 Billion Oxycodone Tablets Dispensed in U.S. 2
(Date:5/21/2013)... 2013 According to a May 13, 2013 ... of Botox,” Botox injections have become the most ... 2002 (Go to goo.gl/8iYbD). Although it is mostly associated with ... The injection makes facial wrinkles less visible by paralyzing facial ... about three months. This means that people who are conscious ...
(Date:5/21/2013)... 2013 Phoseon Technology will present their ... 20th Annual IMI European Ink Jet Conference (June ... Phoseon continues to invest in product development to enable ... UV LED curing in printing applications. Phoseon currently ... market offering both air cooled and water cooled solutions ...
(Date:5/21/2013)... 2013 MedMar Healing Center announces ... Second Harvest Food Bank. Twenty-eight businesses, including MedMar Healing Center, ... food drive. The goal is to raise food to help ... facing their families in recent years. , “We like ... those in need,” explains Douglas Chloupek of MedMar Healing Center. ...
(Date:5/21/2013)... thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, ... acid fragment of prosaposin that significantly reduces metastatic ... lung cancer. The findings suggest that a prosaposin-based ... of cancers. , The study team, led ... Vivek Mittal, PhD, at Weill Cornell Medical College ...
(Date:5/21/2013)... The Brazilian funding agency for scientific and technological research ... of So Paulo, announced an investment estimated in US$ ... Centers (RIDCs) for a period of up to eleven ... and 7. , Funding for the 17 RIDCs ... funding faculty, technicians, support personnel, and infrastructure). Host institutions ...
Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Research at the cutting edge of knowledge 2
... fix for depression. Even if you are under medical care ... ,The December issue of Mayo Clinic Women's HealthSource offers five ... the risk of recurrence. ,1. Keep active. ... most days has been shown to improve mood. Long-term regular ...
... form of food poison. Then, fame came as a ... the 'miracle poison' and used for an increasing number ... of Mayo Clinic Health Letter covers how this drug ... ,Botulinum toxin blocks communication between nerves and muscles. ...
... drugs causing jaw problems have you wondering: Should you stop ... been reports of partial death of a jawbone (osteonecrosis) related ... to the December issue of Mayo Clinic Health Letter. ... — a disease that causes bones to become brittle and ...
... University of Rochester, Low doses of the drug mifepristone ... //and greatly improves the quality of life in women. ... of the journal, Obstetrics and Gynecology. ,Leiomyoma, ... of all women aged 35 to 49. The non-cancerous ...
... by the Department of Radiology at the University of ... the accuracy of diagnosing meniscal tears. ... there is one MR image with an abnormal finding. ... of 174 patients who had knee MR exams then ...
... one more reason why teenage years are perceived as ... the Pandora's Box has opened. //Such teens are prone ... no'vice' contemporaries, a recent insight indicates. ,The Canadian ... abuse tendencies among 15- to 19-year-olds, drawing on the ...
Cached Medicine News:Health News:Five Self-Care Strategies For Depression 2Health News:Mifepristone Reliable For Treating Uterine Fibroids 2Health News:Mifepristone Reliable For Treating Uterine Fibroids 3
DePuy 2 Bone Cement is a unique fast-set digital cement that is the excellent choice for small joint procedures such as the patella, glenoid or other extremity joints....
... Palacos® Bone Cement has clinically proven ... cemented arthroplasty. Palacos® is now available ... an antibiotic loaded bone cement cleared ... of a two-stage revision after infection ...
... System for Two-Dimensional Mapping of the ... uniquely merges two sophisticated measurement techniques, ... flowmetry, to a new kind of ... of the retinal micro-circulation., ,Using an ...
... block tear drainage through the canaliculus, synthetic absorbable ... symptoms:, Indicated for use in the treatment ... components of various ocular surface diseases, May be ... related complications and to enhance the retention of ...
Medicine Products: